On March 25, 2026, The IQVIA Institute published its Global R&D Trends 2026 report, arguing that biopharmaceutical R&D proved resilient in 2025 even as the work got harder. Funding and dealmaking clustered around higher-value science, emerging biopharma, and China-linked activity. At the same time, IQVIA says growing scientific complexity, longer timelines, and uneven trial country use and drug availability are straining productivity—pushing sponsors toward internal efficiency levers and regulatory reforms.
What the Global R&D Trends 2026 report actually says
According to IQVIA’s summary, the center of gravity shifted toward deals and pipelines tied to platform science and smaller innovators. That tilt reinforced a long-running pattern: emerging biopharma often takes the early science risk, while larger companies fund, partner, or buy once signals strengthen. IQVIA pairs that with a warning: more complex modalities and designs extend development time, and regional disparities in access and trial participation remain stubborn.
Global R&D Trends 2026 frames the squeeze clearly. More money is flowing to a narrower set of bets, while each bet is harder to progress and bring to market. That combination can inflate cost per approval and slow patient reach, unless sponsors find time savings inside their own operations or regulators clear paths that remove avoidable friction.
Why the productivity squeeze matters for patients and pipelines
When timelines stretch, fewer programs finish. Companies respond by pruning portfolios sooner, raising the evidence bar for mid-stage investments, and concentrating on indications with cleaner endpoints. That can be rational for shareholders yet tough for patients in smaller markets or rarer conditions. IQVIA’s read—that disparities in drug availability and trial country utilization persist—points to the same risk: if activity keeps clustering, access gaps can widen.
This is where the report’s emphasis on efficiency and rulemaking lands. Internal gains—faster site start-up, better protocol discipline, tighter data quality loops—shave months without changing the science. On the policy side, regulators are already updating trial playbooks. The U.S. Food and Drug Administration issued guidance on decentralized clinical trials to lower patient burden and broaden reach. Global efforts to refresh Good Clinical Practice, including the ICH E6(R3) update, move in the same direction: fit-for-purpose oversight that keeps participants safe while cutting red tape.
Efficiency levers and the policy track IQVIA highlights
The report’s call for internal efficiency levers is specific. It nudges sponsors to standardize operations, reduce protocol bloat, and make earlier, cleaner go/no-go calls. That’s not a spend-more answer. It’s a do-less-bad-work answer. The prize is shorter cycles and higher confidence in the data that remain.
On the public side, Global R&D Trends 2026 also ties gains to regulatory reform. Convergence on core expectations helps sponsors build once, file many times, and plan global trials without reinventing process maps per country. IQVIA’s concern over trial country utilization sits at the center of that. If more countries contribute patients and data, approvals can reflect real-world diversity, and access can spread faster after launch. The World Health Organization has long documented the human cost of uneven access; IQVIA’s findings suggest operations and rules, not just science, are gating progress.
The China question and concentration risk
IQVIA links part of the deal momentum to China-linked activity. That opens doors to talent, data, and manufacturing depth. It also concentrates exposure. Policy shifts, data localization rules, or cross-border controls can change risk in a quarter, not a cycle. For multinationals, the right move is contingency planning—parallel suppliers, dual data strategies, and partnership terms that survive stress.
The broader concentration in high-value science carries a different risk. If too much capital tracks the same modalities, crowding can push marginal programs to chase the same endpoints, clogging sites and straining reviewers. The smartest sponsors will differentiate on indication strategy and trial design, not only on the platform they pick.
What to watch next from Global R&D Trends 2026
Two signals will show whether the field took IQVIA’s message seriously. First, watch cycle times for study start-up and first-patient-in; if internal changes stick, those should improve before approval counts do. Second, track the country mix of Phase II and III trials; meaningful shifts would validate the push to diversify participation. A third tell sits in deal terms: more option-based partnerships and earlier-stage alliances would confirm that sponsors want flexibility as programs get harder.
For patients, the metric that matters is availability. If the gaps IQVIA flags start to narrow—more launches crossing more borders sooner—the approach works. If not, the next wave of R&D spend will buy less progress for more money.
Global R&D Trends 2026 sets a clear test for the year ahead: operational discipline plus practical rulemaking, measured in months saved and medicines reached. The science looks strong. The question is whether the system around it can keep up. For more on this, see bloomberg.com and nytimes.com.